ERBB2 and breast carcinoma: Several clinical trials have consistently demonstrated that patients with breast cancer benefit from targeted therapies, such as HER2-targeted agents, only if they exhibit HER2 protein overexpression or amplification of the ERBB2 gene confirmed via in situ hybridization (ISH) techniques [6,7].